NCI Featured Clinical Trials

Experimental Antibody for Treatment-Resistant Liver Cancer

2012-05-15 00:00:00.0

In this trial, patients with unresectable hepatocellular carcinoma who are ineligible for liver transplants or other localized therapies, and who did not benefit from or could not tolerate treatment with sorafenib, will be treated with intravenous TRC105 every 2 weeks.

Surgical and Radiation Therapies for High-Risk Early Lung Cancer

2012-05-01 00:00:00.0

Patients with high-risk operable stage I lung cancer will be randomly assigned to undergo either sublobar resection, with or without brachytherapy, or stereotactic body radiation therapy.

Testing Vascular Disruption Combined with Chemotherapy for Advanced Solid Tumors

2012-04-17 00:00:00.0

In this phase I/II trial, doctors will assess the safety and tolerability of intravenous crolibulin and cisplatin in patients with advanced solid tumors, establish the maximum tolerated dose for the combination, and randomly assign patients with anaplastic thyroid cancer to receive crolibulin and cisplatin or cisplatin alone.

Virus Therapy for Extensive-Stage Small Cell Lung Cancer

2012-04-03 00:00:00.0

In this clinical trial, patients with extensive-stage small cell lung cancer who have received platinum-based chemotherapy will be randomly assigned to receive Seneca Valley virus-001 intravenously or an intravenous placebo.

Combining Systemic Therapies for Patients with Advanced Liver Cancer

2012-03-20 00:00:00.0

In this phase III trial, patients with unresectable, locally advanced or metastatic primary liver cancer who have good liver function (Child-Pugh score A) will receive sorafenib and be randomly assigned to also receive either doxorubicin or no additional therapy.

Exploring the Anticancer Potential of Valproic Acid in Advanced Thyroid Cancer

2012-03-07 00:00:00.0

In this trial, patients with advanced thyroid cancers of follicular cell origin whose tumors are not sensitive to radioactive iodine therapy will take valproic acid for 10 weeks and then undergo a radioactive iodine uptake test.

Surgical Removal of Primary Tumor for Metastatic Breast Cancer

2012-02-21 00:00:00.0

In this clinical trial, women with newly diagnosed metastatic breast cancer who are undergoing systemic therapy and whose disease does not progress within 16 weeks of starting that therapy will be randomly assigned to continue systemic therapy or to undergo surgical resection of their primary tumor.

First-in-Humans Study of New Immunotherapy Agent

2012-01-24 00:00:00.0

In this first-in-humans clinical trial of interleukin-15 (IL-15), patients with metastatic melanoma or metastatic renal cell cancer who have not benefited from other therapies will be given IL-15 by intravenous injection once a day for 12 days.

Making Decisions about Cancer Prevention Medications for Breast Cancer

2012-01-10 00:00:00.0

In this study, women age 35 or older who discuss the use of drugs called SERMs for breast cancer prevention with a health care provider will be asked to complete a questionnaire about their discussion and whether they have come to a decision about using a SERM for risk reduction, as well as a second questionnaire about their decision-making process.

Comparing Postoperative Radiation Therapies for Brain Metastases

2011-12-13 00:00:00.0

In this clinical trial, patients with one to four brain metastases who have had at least one of the metastatic tumors removed surgically will be randomly assigned to undergo whole-brain radiation therapy or stereotactic radiosurgery.